MBL77 - AN OVERVIEW

Unfit patients even have the choice of venetoclax in addition obinutuzumab (VO) as frontline therapy. This is based over a stage III trial that in contrast VO with ClbO in aged/unfit patients.113 VO was superior concerning response rate and progression-free of charge survival, and experienced a similar basic safety profile. In this particular trial